Pipeline Programs↗
Distinct drugs in development (Preclinical–Phase 3)
Indications↗
Distinct diseases across all programs
Clinical Trials↗
All sponsored trials (all statuses)
Orange Book Patents
Across 11 drugs with upcoming expirations
Activity
Details
Company Overview
—
Mkt Cap
—
Revenue
—
Cash
Regulatory
Intelence — INTELENCE
Application NDA022187 (NDA)
Olysio — OLYSIO
Application NDA205123 (NDA)
Topamax — TROKENDI XR
Application NDA201635 (NDA)
Invokana — INVOKANA
Application NDA204042 (NDA)
Oxytrol — OXYTROL FOR WOMEN
Application NDA202211 (NDA)
Topamax — QUDEXY XR
Application NDA205122 (NDA)
Vermox — VERMOX
Application NDA208398 (NDA)
Xarelto — XARELTO
Application NDA022406 (NDA)
Risperdal — PERSERIS KIT
Application NDA210655 (NDA)
Spravato — SPRAVATO
Application NDA211243 (NDA)
Ultram — QDOLO
Application NDA214044 (NDA)
Sirturo — SIRTURO
Application NDA204384 (NDA)
Xarelto — XARELTO
Application NDA215859 (NDA)
Topamax — EPRONTIA
Application NDA214679 (NDA)
Erzofri — INVEGA HAFYERA
Application NDA207946 (NDA)
Risperdal — UZEDY
Application NDA213586 (NDA)
Risperdal — RYKINDO
Application NDA212849 (NDA)
Erzofri — ERZOFRI
Application NDA216352 (NDA)
Risperdal — RISVAN
Application NDA214835 (NDA)
Edurant Ped — EDURANT PED
Application NDA219016 (NDA)
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)